In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
Janssen Biotech has signed an exclusive, worldwide license agreement with Sweden’s privately-held biotech firm Alligator Bioscience for ADC-1013, an immuno-oncology agent currently in Phase I clinical studies. 13 August 2015
Bristol-Myers Squibb said that the FDA has extended the action date for its application for expanded approval of Opdivo (nivolumab) to include patients with previously-untreated advanced melanoma. 13 August 2015
Biotechnology firm Aslan Pharmaceuticals on Thursday said its drug candidate for bile duct cancer has been assigned orphan drug designation by the US Food and Drug administration. 13 August 2015
Roche today released positive results from the Phase II M13-982 study of venetoclax, an investigational drug being developed in partnership with the USA’s AbbVie and Roche subsidiary Genentech. 12 August 2015
In a second accord announced within a week, USA-based Immune Design has entered into a clinical trial collaboration with Genentech, a subsidiary of Swiss pharma giant Roche. 12 August 2015
Genmab reported a surge in first half 2015 operating income year-on-year driven by a one-time gain and lower expenses as revenue dropped 23%. 12 August 2015
The global breast cancer therapeutics market was valued at $55.5 million in 2015 and is estimated to reach $7,853.1 million in 2023 at a CAGR of 58.3% from 2015 to 2023, according to a new market research report from Transparency Market Research. 11 August 2015
USA-based Inovio Pharmaceuticals has entered into a license agreement and collaboration with MedImmune, the global biologics R&D arm of Anglo-Swedish pharma major AstraZeneca. 10 August 2015
Dr Reddy's Laboratories has entered into a strategic collaboration with USA-based Amgen to market and distribute three Amgen drugs in India in the areas of oncology and cardiology. 6 August 2015
Heptares Therapeutics has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialize the adenosine A2A receptor antagonist HTL-1071. 6 August 2015
GlobeImmune has revealed that Celgene Corp has exercised its option under a 2009 agreement to exclusively license GI-6207, a Tarmogen product candidate targeting cancers that express carcinoembryonic antigen (CEA). 6 August 2015
US biotech firm Aveo Oncology has entered into an exclusive license agreement with a subsidiary of Pharmstandard, the largest Russian pharmaceutical group. 6 August 2015
The UK’s National Institute for health and Care Excellence (NICE) has opened a second consultation on preliminary draft guidance on Lynparza (olaparib) from AstraZeneca, asking the company for more information. 6 August 2015
MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca has entered into an exclusive clinical trial collaboration with oncology specialist Mirati Therapeutics. 5 August 2015
Oasmia Pharmaceutical on Tuesday reported positive results for its cancer drug Paclical (paclitaxel) following a head-to-head comparison study with Celgene's Abraxane (paclitaxel). 4 August 2015
Sorrento Therapeutics has entered into an exclusive licensing agreement to develop and commercialize multiple pre-specified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited. 3 August 2015
Shares of Clovis Oncology gained nearly 2% to $86.21 in early trading today, when the company announced regulatory filings in the USA and Europe for its lung cancer drug candidate rociletinib. 3 August 2015
Lexicon Pharmaceuticals and its partner Ipsen have announced positive results from their TELESTAR Phase III clinical trial of oral telotristat etiprate. 3 August 2015